Home
overview
With 2.6 million cancer cases being diagnosed each year in Europe and The United States, advances in imaging in oncology are paramount to the safer, quicker and more efficient detection of cancer.

Therefore, SMi is proud to announce its 4th Annual Conference on Imaging in Oncology. Imaging in Oncology is a rapidly advancing field that can significantly impact the diagnosis, treatment and monitoring of cancer. This conference will gather the top industry experts to discuss, debate and learn about the newest developments of imaging in oncology, and to address that Europe is still struggling to establish an ad hoc regulatory system.

       Discover the future of imaging in oncology by hearing about the newest breakthrough techniques and technology.
       Obtain comprehensive insight into the world of imaging in oncology from all stages of research and development.
       Receive accounts of case studies from the field of imaging in oncology.
       Learn about the role of imaging in oncology at all stages from diagnosis through to treatment
       Examine regulatory challenges and how these can be overcome to take the next step in establishing a unified system for Europe.


Confirmed speakers include:

  • Helen Young, Discovery Medicine Imaging, AstraZeneca
  • Philip Murphy, Director, GlaxoSmithKline
  • Hans Winkler, Senior Director, Translational Research Oncology, Johnson & Johnson
  • Werner Scheuer, Group Leader, Preclinical Optical Imaging, Roche
  • Peter Allegrini, Preclinical Imaging Expert, Novartis
  • Detlef Stiller, Laboratory Head, Boehringer-Ingelheim
  • Sigrid Stroobants, Oncologist, EORTC
  • Paul Maguire, Associate Director, Global Clinical Technologies, Pfizer


Who should attend:

Directors, heads and managers of:

-          Discovery Medicine-          Cancer & Infection
-          Biomedical Imaging-          Pharmacology
-          Clinical Technology-          Clinical Diagnostics
-          Oncology-          Diagnostic Imaging
-          Oncology Imaging-          Molecular Imaging
-          Specialized Therapeutics-          Neuroimaging and neurology
-          Oncology technology-          Clinical strategy


Who will attend:

SMi's events are attended by the highest level of industry experts and last year's Imaging and Oncology Conference was no exception. Here is a breakdown of the 2007 Imaging in Oncology event, and who you can expect will be there again in 2008.

Seniority

Region

Function

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Philip Murphy

Philip Murphy, Director of Imaging, Oncology Medicines Development Centre, GlaxoSmithKline

9:10 IMAGING IN ONCOLOGY DRUG DEVELOPMENT

Helen Young

Helen Young, Discovery Medicine Imaging RCS (PET), AstraZeneca

·                 Framework of imaging biomarkers
·                 Qualification for decision making and portfolio prioritisation
·                 Examples in oncology drug development
·                 Qualified” to surrogate: role of C-Path and biomarker consortium

9:50 IMAGING IN ANGIOGENESIS IN CLINICAL TRIALS

Philip Murphy

Philip Murphy, Director of Imaging, Oncology Medicines Development Centre, GlaxoSmithKline

·                How different methods can be used to evaluate pharmacological response
·                The impact of building a relationship between tumour response and drug exposure for angiogenesis drug development
·                What functional imaging endpoints are most appropriate for imaging angiogenesis?
·                Overcoming issues during the implementation of functional imaging with a focus on DCE-MRI

10:30 Morning Coffee

11:00 BRIDGING THE PRECLINICAL AND CLINICAL INTERFACE

Peter Allegrini

Peter Allegrini, Preclinical Imaging Expert, Novartis

  • Imaging techniques in preclinical cancer research
  • The use of imaging techniques in animal models to bridge preclinical research and clinical development
  • What can imaging contribute to PoC studies
  • The use of optical imaging in cancer drug development

11:40 HIGH-CONTENT ANALYSIS IN PRECLINICAL ONCOLOGY DRUG RESEARCH

Stefan Prechtl

Stefan Prechtl, High-Content Analysis, AD-HTS, Bayer Healthcare AG

·                 Setup of a panel of useful standard HCA applications
·                 Support Oncology projects with target related functional & mechanistic HCA assays.
·                 Select the most meaningful HCA application for analysing cellular functional relevance of compounds.
·                 Select the most convenient and appropriate HCA instrument.
·                 Utilize HCA driven results of cellular impact for prominent conclusions at an early stage of lead discovery.

12:20 Networking Lunch

13:50 TRANSLATIONAL IMAGING USING HIGH RESOLUTION AND HIGH SENSITIVITY NANOSPECT/CT™

York Hamisch

York Hamisch, Vice President, Bioscan Europe Ltd

·        Revolutionary MMP™-Technology of NanoSPECT™/CT allows to image mice and rats with same visual acuity as humans

·        High quantitative accuracy enables exact and repeatable measurements

·        Kinetic and dynamic imaging without detector rotation due to very high sensitivity using up to 64 pinholes

·        Seamless and accurate complementary morphological information with on axis CT and automatic registration

14:30 Afternoon Tea

15:00 FDG – PET IMAGING IN MULTI-CENTRE ONCOLOGY CLINICAL TRIALS

Eric Perlman

Eric Perlman, Director, Molecular Imaging and Biomarkers, Radpharm

·                Practical aspects of FDG-PET in Oncology Imaging

·                Methodologies and Procedures to obtain reliable quantitative data

·                Using FDG-PET/CT in Clinical Trials

·                Design and Limitations of PET in Multi-center Trials

15:40 USE OF FUNCTIONAL IMAGING FOR IMAGE GUIDED RADIOTHERAPY: PRE-CLINICAL AND CLINICAL DATA

Karin Haustermans

Karin Haustermans, Chair of the Radiation Oncology Group of EORTC, University Hospital Gasthuisberg K U Leuven

  •  How FDG-PET can be used in radiotherapy treatment planning
  • The impact of re-imaging during radiotherapy on dose distribution
  • Do other PET tracers play a role in image guided radiotherapy
  • Can PET be used for dose painting by numbers

  • 16:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Helen Young

    Helen Young, Discovery Medicine Imaging RCS (PET), AstraZeneca

    9:10 THERANOSTICS - FUTURE OR REALITY?

    Hans-Juergen Arens

    Hans-Juergen Arens, Manager Medical & Scientific Development, Europe, Middle East & Africa, Abbott

    • Meaningful diagnostic practice
    • The need for biomarkers
    • Patient stratification by molecular mechanism
    • Testing for Her-2/neu and other oncology examples
    • Diagnostic implications for HIV patient management
    • Patient benefit and economical value - current examples and future
    direction

    9:50 USE OF FDG-PET IN CLINICAL TRIALS AND DRUG DEVELOPMENT

    Sigrid Stroobants

    Sigrid Stroobants, Oncologist, UZ Gasthuisberg Leuven

  • How FDG-PET can be used to predict growth rate and grade of a tumour
  • Using FDG-PET to predict response to chemotherapy
  • Overcoming the challenges of using FDG-PET in clinical trials
  • Implementing FDG-PET into drug development
  • 10:30 Morning Coffee

    11:00 NEW APPROACHES IN ONCOLOGY IMAGING

    David Gauden

    David Gauden, Head of Imaging Technology Operations, GE Healthcare

  • New approaches, beyond CT and FDG: Novel PET, optical and intra-surgical imaging opportunities
  • Imaging for patient stratification and therapy selection
  • Imaging in oncology drug development
  • Imaging standardisation in multi-centre trials - the best chance of meeting the endpoint?
  • 11:40 BENEFITS OF FUNCTIONAL IMAGING IN EARLY PHASE TRIALS

    Edward Ashton

    Edward Ashton, Chief Scientific Officer, VirtualScopics Inc

  • New approaches to assess potential efficacy in early stages of drug development
  • Benefits and potential pitfalls with functional and molecular imaging
  • Efficient and effective ways to integrate imaging with early phase oncology trials
  • 12:20 Networking Lunch

    13:50 RECENT DEVELOPMENTS IN OPTICAL IMAGING FOR ONCOLOGY

    Alexandra De Lille

    Alexandra De Lille, Director of Technical Applications, Caliper Life Sciences

  • Routinely monitor and track tumor development in vivo
  • Observe specific oncogenic events in vivo using reporter gene fusions
  • Screen oncogenic events and drugs in a HTS manner in cells and,
  • Seamlessly translate these assays in vivo
  • Monitor multiple oncogenic events in vivo using both bioluminescent and fluorescent reporters
  • Three dimensional reconstruct and quantify tumors growth/regression in vivo.
  • 14:30 Afternoon Tea

    15:00 OPTICAL IMAGING IN ANTI-CANCER DRUG DEVELOPMENT

    Werner  Scheuer

    Werner Scheuer, Group Leader, Preclinical Optical Imaging, Pharmacology TR-PD, Pharmaceutical Research , Roche Diagnostics

    15:40 ISSUES AFFECTING QUANTITIATION OF IMAGING STUDIES

    Paul Maguire

    Paul Maguire, Director, Global Clinical Technologies, Pfizer Global R&D

  • Current standards
  • Instrumentation
  • Analysis
  • Future directions
  • 16:20 Chairman’s Closing Remarks and Close of Day One

    +

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.